JP2018530554A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530554A5 JP2018530554A5 JP2018517255A JP2018517255A JP2018530554A5 JP 2018530554 A5 JP2018530554 A5 JP 2018530554A5 JP 2018517255 A JP2018517255 A JP 2018517255A JP 2018517255 A JP2018517255 A JP 2018517255A JP 2018530554 A5 JP2018530554 A5 JP 2018530554A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- cancer
- tumor
- tumors
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236280P | 2015-10-02 | 2015-10-02 | |
| US62/236,280 | 2015-10-02 | ||
| PCT/US2016/054924 WO2017059319A2 (en) | 2015-10-02 | 2016-09-30 | Combination therapy of bromodomain inhibitors and checkpoint blockade |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530554A JP2018530554A (ja) | 2018-10-18 |
| JP2018530554A5 true JP2018530554A5 (enExample) | 2019-11-07 |
Family
ID=57137298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517255A Pending JP2018530554A (ja) | 2015-10-02 | 2016-09-30 | ブロモドメイン阻害薬及びチェックポイント阻害薬による併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190192532A1 (enExample) |
| EP (1) | EP3355922A2 (enExample) |
| JP (1) | JP2018530554A (enExample) |
| KR (1) | KR20180081507A (enExample) |
| CN (1) | CN108289957A (enExample) |
| AR (1) | AR107500A1 (enExample) |
| AU (1) | AU2016331190A1 (enExample) |
| BR (1) | BR112018006689A2 (enExample) |
| CA (1) | CA2999523A1 (enExample) |
| CL (1) | CL2018000853A1 (enExample) |
| HK (1) | HK1256269A1 (enExample) |
| IL (1) | IL258212A (enExample) |
| MA (1) | MA43037A (enExample) |
| MX (1) | MX2018003824A (enExample) |
| PE (1) | PE20181068A1 (enExample) |
| WO (1) | WO2017059319A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101510065B1 (ko) * | 2005-06-08 | 2015-04-07 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| US8986702B2 (en) | 2008-05-16 | 2015-03-24 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| DK2966084T3 (en) | 2008-08-28 | 2018-08-06 | Taiga Biotechnologies Inc | MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC |
| MX384074B (es) | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| MX373121B (es) | 2010-05-14 | 2020-04-30 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| AU2013292330B2 (en) | 2012-07-20 | 2018-07-12 | Htyr Acquisition Llc | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| EP3066101B1 (en) | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| KR20160130778A (ko) | 2014-02-28 | 2016-11-14 | 텐샤 세러퓨틱스 인코포레이티드 | 고인슐린혈증과 관련된 질환의 치료 |
| AU2015339511B2 (en) | 2014-10-27 | 2020-05-14 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
| MX389710B (es) | 2016-05-27 | 2025-03-20 | Agenus Inc | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos. |
| CN113786476A (zh) | 2016-12-02 | 2021-12-14 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| JP7169005B2 (ja) * | 2018-01-16 | 2022-11-10 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのジフェニルアミノピリミジン系化合物 |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| US12187686B2 (en) * | 2018-09-07 | 2025-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | BRD4-JAK2 inhibitors |
| TWI816881B (zh) * | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 用於治療三陰性乳癌之組合療法 |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| CN109666723B (zh) * | 2019-01-22 | 2022-04-15 | 南通大学 | 一种基于pdl1/pdl2超增强子的免疫检测点抑制剂的应用 |
| CN113874033A (zh) | 2019-04-08 | 2021-12-31 | 泰加生物工艺学公司 | 用于冷冻保存免疫细胞的组合物和方法 |
| JP2022532608A (ja) * | 2019-05-14 | 2022-07-15 | タイガ バイオテクノロジーズ，インク． | Ｔ細胞疲弊を処置するための組成物および方法 |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| US20230093080A1 (en) * | 2019-07-15 | 2023-03-23 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| TWI867086B (zh) * | 2019-11-05 | 2024-12-21 | 加拿大商瑞斯弗洛吉克斯公司 | 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法 |
| KR102420262B1 (ko) * | 2019-11-26 | 2022-07-13 | 주식회사 베노바이오 | 신규한 퀘르세틴 리독스 유도체 및 bet 억제제로서의 용도 |
| EP4072591A4 (en) | 2019-12-10 | 2024-06-05 | Kymera Therapeutics, Inc. | IRAQ DEGRADER AND USES THEREOF |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| BR112023000047A2 (pt) | 2020-07-02 | 2023-03-14 | Incyte Corp | Compostos de ureia tricíclicos como inibidores da v617f da jak2 |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| WO2022147465A1 (en) | 2020-12-30 | 2022-07-07 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| TW202245788A (zh) | 2021-02-15 | 2022-12-01 | 美商凱麥拉醫療公司 | Irak4降解劑及其用途 |
| AU2022227673A1 (en) * | 2021-02-25 | 2023-08-17 | Impact Biomedicines, Inc. | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
| KR20240163688A (ko) | 2022-03-17 | 2024-11-19 | 인사이트 코포레이션 | Jak2 v617f 억제제로서의 삼환계 우레아 화합물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2496580B1 (en) * | 2009-11-05 | 2013-12-11 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
| US9301962B2 (en) * | 2010-05-14 | 2016-04-05 | Baylor College Of Medicine | Male contraceptive compositions and methods of use |
| MX384074B (es) * | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| US9249161B2 (en) * | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| JP2016513117A (ja) * | 2013-02-22 | 2016-05-12 | バイエル ファーマ アクチエンゲゼルシャフト | 過剰増殖性疾患を治療するためのｂｅｔタンパク質阻害剤としてのピロロ−およびピラゾロ−トリアゾロジアゼピン類 |
| HK1212345A1 (en) * | 2013-02-22 | 2016-06-10 | Bayer Pharma Aktiengesellschaft | 4-substituted pyrrolo- and pyrazolo-diazepines |
| CN105050595A (zh) * | 2013-03-15 | 2015-11-11 | 基因泰克公司 | 通过抑制含布罗莫结构域蛋白brd7和brd9治疗th2介导的疾病 |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| KR20160037201A (ko) * | 2013-08-06 | 2016-04-05 | 온코에틱스 게엠베하 | Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법 |
| KR20160060765A (ko) * | 2013-10-11 | 2016-05-30 | 제넨테크, 인크. | 암 면역요법을 위한 cbp/ep300 브로모도메인 억제제의 용도 |
| HUE054183T2 (hu) * | 2013-12-24 | 2021-08-30 | Bristol Myers Squibb Co | Triciklusos vegyület rákellenes szerekként |
-
2016
- 2016-09-30 EP EP16781957.2A patent/EP3355922A2/en not_active Withdrawn
- 2016-09-30 WO PCT/US2016/054924 patent/WO2017059319A2/en not_active Ceased
- 2016-09-30 AR ARP160103015A patent/AR107500A1/es unknown
- 2016-09-30 BR BR112018006689A patent/BR112018006689A2/pt not_active IP Right Cessation
- 2016-09-30 HK HK18115329.0A patent/HK1256269A1/zh unknown
- 2016-09-30 AU AU2016331190A patent/AU2016331190A1/en not_active Abandoned
- 2016-09-30 US US15/764,131 patent/US20190192532A1/en not_active Abandoned
- 2016-09-30 KR KR1020187012018A patent/KR20180081507A/ko not_active Withdrawn
- 2016-09-30 MX MX2018003824A patent/MX2018003824A/es unknown
- 2016-09-30 MA MA043037A patent/MA43037A/fr unknown
- 2016-09-30 JP JP2018517255A patent/JP2018530554A/ja active Pending
- 2016-09-30 PE PE2018000491A patent/PE20181068A1/es unknown
- 2016-09-30 CA CA2999523A patent/CA2999523A1/en not_active Abandoned
- 2016-09-30 CN CN201680070462.8A patent/CN108289957A/zh active Pending
-
2018
- 2018-03-19 IL IL258212A patent/IL258212A/en unknown
- 2018-04-02 CL CL2018000853A patent/CL2018000853A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202210065B (en) | Interleukin-21 muteins and methods of treatment | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| PH12021551487A1 (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| IL265541B2 (en) | Bispecific antibodies and compounds containing them for the treatment of cancer | |
| MX2019009967A (es) | Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas. | |
| MX373927B (es) | Anticuerpos biespecíficos con funciones efectoras reducidas. | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| FI3377103T4 (fi) | Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| EP4219563A3 (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| EA201691361A1 (ru) | Антитела к lag-3 для лечения гематологических злокачественных опухолей | |
| MX2019002474A (es) | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. | |
| JP2019501145A5 (enExample) | ||
| MY200162A (en) | Anti-gitr antibodies and uses thereof | |
| EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| HRP20202042T1 (hr) | Modulacija tumorske imunosti | |
| EA201890158A1 (ru) | Антитела против ntb-a и связанные композиции и способы | |
| JP2017524715A5 (enExample) | ||
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| AR107500A1 (es) | Terapia de combinación de inhibidores de bromodominio y moduladores inmunitarios | |
| EA201491265A1 (ru) | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию | |
| CR20200463A (es) | Anticuerpos |